Print
Email
Print Edition StoriesTuesday, July 21, 2009
Third Rock Ventures names new partners
By Mass High Tech staff
Following the Clean Energy Council Fellows
MHT's Galen Moore: Hiring trends and opportunities
MHT's Michelle Lang: Local tech execs tackle the Boston Marathon
Boston life sciences-focused venture capital firm Third Rock Ventures LLC has named two new venture partners, Philip Reilly and Gregory Verdine, and a recruiting partner, Craig Greaves, to the firm.
Reilly joins the firm with the intention of focusing on companies associated with genetic disorders, in particular. He has served previously as CEO and chairman of the board of directors at Interleukin Genetics Inc. (AMEX: ILI), a Waltham-based genetic biomarker test maker. Author of six books and co-author of more than 100 scholarly articles, Reilly has also served as executive director of the Eunice Kennedy Shriver Center for Mental Retardation Inc. and as an assistant professor at Tufts University School of Medicine and Harvard Medical School.
Reilly graduated fro Yale University with his M.D. and from Columbia University with his J.D.
Verdine will be responsible at Third Rock for supporting “the firm’s science, planning and analysis of potential new entrpreneurial ventures.” He works currently as director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute, and as the Erving Professor of Chemistry at Harvard University. His work spans coverage and appoints in Harvard’s molecular and cellular biology, stem cell and regenerative biology and chemistry and chemical biology departments. Verdine has co-founded Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals and Ontorli Pharmaceuticals. He was also the founding scientific advisor to Vertex Pharmaceuticals Inc.
As Third Rock recruiting partner, Greaves will be responsible for recruiting entrepreneurs-in-residence, associates, advisors and consultants for the firm. Prior to joining Third Rock, Greaves worked as director of talent acquisition at Cubist Pharmaceuticals Inc. and as director of employment at Biogen Idec Inc.
Third Rock Ventures raised its first fund in 2007, worth $378 million.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
